Hsbc Holdings PLC Has $9.99 Million Holdings in Sanofi $SNY

Hsbc Holdings PLC increased its position in shares of Sanofi (NASDAQ:SNY) by 3,426.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 205,917 shares of the company’s stock after purchasing an additional 200,077 shares during the period. Hsbc Holdings PLC’s holdings in Sanofi were worth $9,987,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Bayban bought a new stake in Sanofi in the 4th quarter valued at $47,000. Rehmann Capital Advisory Group lifted its holdings in shares of Sanofi by 8.4% during the 4th quarter. Rehmann Capital Advisory Group now owns 14,040 shares of the company’s stock worth $680,000 after acquiring an additional 1,083 shares during the period. Virtu Financial LLC boosted its position in shares of Sanofi by 212.9% during the 4th quarter. Virtu Financial LLC now owns 31,550 shares of the company’s stock valued at $1,529,000 after acquiring an additional 21,466 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Sanofi by 24.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,108 shares of the company’s stock valued at $151,000 after acquiring an additional 619 shares in the last quarter. Finally, Compound Planning Inc. increased its stake in Sanofi by 15.5% in the fourth quarter. Compound Planning Inc. now owns 16,680 shares of the company’s stock valued at $808,000 after acquiring an additional 2,234 shares during the period. 14.03% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a research report on Monday, April 20th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Citigroup reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Argus raised Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Finally, Morgan Stanley set a $52.00 target price on Sanofi in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $51.00.

Sanofi Trading Up 1.1%

Shares of Sanofi stock opened at $41.80 on Friday. The stock has a market capitalization of $101.34 billion, a P/E ratio of 11.68, a price-to-earnings-growth ratio of 1.02 and a beta of 0.34. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company has a 50-day simple moving average of $44.26 and a 200 day simple moving average of $46.06. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th were paid a $2.4225 dividend. This represents a dividend yield of 559.0%. This is an increase from Sanofi’s previous annual dividend of $2.04. The ex-dividend date was Monday, May 4th. Sanofi’s dividend payout ratio is presently 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.